TLSA: Nasally-administered Foralumab Trial in SPMS Patient
By John Vandermosten, CFA
NASDAQ:TLSA | LSE:TILS
READ THE FULL TLSA RESEARCH REPORT
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 24)